• Plus Therapeutics, Piramal Ink Master Services Agreement contractpharma
    March 24, 2021
    ​Plus Therapeutics has entered into a master services agreement (MSA) with Piramal Pharma Solutions (PPS) for the development, manufacture, and supply of Plus’ Rhenium NanoLiposome (RNL) intermediate drug product.
PharmaSources Customer Service